51 completed, 8 terminated, 5 recruiting, 4 unknown. 74 Phase 1, 20 Phase 2.
Follow BeiGene: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sonrotoclax Plus Azacitidine in Patients With MDS-IB2 Sonrotoclax, Azacitidine (AZA) - Myelodysplastic Syndromes, High Risk | Phase 1 / Phase 2 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 60 | 2026-10-15 | 2026-10-21 |
| A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma Tislelizumab, FLOT Chemotherapy - Esophagogastric Junction Adenocarcinoma, Gastric Adenocarcinoma | Phase 1 | Recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 18 | 2025-12-12 | 2025-12-19 |
| Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma Zanubrutinib, Methotrexate, Polatuzumab Vedotin - CNS Lymphoma | Phase 1 | Recruiting | Juan P. Alderuccio, MD | 20 | 2025-04-17 | 2026-05-14 |
| Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants BGB-16673, Itraconazole, Phenytoin - Healthy Volunteers | Phase 1 | Completed | BeiGene | 37 | 2025-04-03 | 2026-08-24 |
| A Study of How [14C]-BGB-16673 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Participants [14C]-BGB-16673 - Healthy Volunteers | Phase 1 | Completed | BeiGene | 8 | 2025-01-24 | 2025-05-01 |
| A Study of Different Forms of BGB-43395 and Food Effect in Healthy Participants BGB-43395 - Healthy Volunteers | Phase 1 | Completed | BeiGene | 51 | 2025-01-14 | 2025-09-04 |
| A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors BGB-B3227, Tislelizumab, Chemotherapy - Advanced Cancer, Advanced Solid Tumor | Phase 1 | Terminated | BeiGene | 35 | 2024-09-11 | 2026-03-16 |
| A Study to Evaluate the Effects of Phenytoin and Itraconazole on Sonrotoclax (BGB-11417) in Healthy Volunteers Phenytoin, Itraconazole, sonrotoclax - Not Determined | Phase 1 | Completed | BeiGene | 30 | 2024-08-19 | 2024-11-27 |
| Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC Trametinib, Anlotinib, Tislelizumab - KRAS Mutation-Related Tumors, Advanced Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Chest Hospital | 60 | 2024-07-01 | 2024-06-13 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases BGB-45035, Placebo - Healthy Participants, Healthy Subjects | Phase 1 | Completed | BeiGene | 203 | 2024-06-20 | 2026-06-22 |
| A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors BG-68501, Fulvestrant, BGB-43395 - Breast Cancer, Small Cell Lung Cancer | Phase 1 | Active not recruiting | BeiGene | 103 | 2024-03-11 | 2026-10-20 |
| Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants BGB-B167, Tislelizumab - Solid Tumors | Phase 1 | Withdrawn | BeiGene | 2024-03-01 | 2023-11-29 | |
| Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Tislelizumab IV, Tislelizumab SC, Histology-Based Chemotherapy Doublet - Non-small Cell Lung Cancer | Phase 1 | Completed | BeiGene | 62 | 2023-11-16 | 2026-08-12 |
| A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies PRT2527, Zanubrutinib, Venetoclax - Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | Phase 1 | Completed | Prelude Therapeutics Incorporated | 86 | 2023-09-12 | 2026-01-26 |
| BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors BGB-A3055, Tislelizumab, Chemotherapy - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Terminated | BeiGene | 99 | 2023-08-21 | 2026-03-13 |
| A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors BGB-30813, Tislelizumab - Advanced Solid Tumors | Phase 1 | Terminated | BeiGene | 44 | 2023-07-19 | 2025-09-16 |
| A Study to Investigate the Absorption, Metabolism and Excretion of [14C]-BGB-11417 [14C]-BGB-11417 - Healthy Volunteers | Phase 1 | Completed | BeiGene | 6 | 2023-05-22 | 2025-04-17 |
| Bioequivalence of a Zanubrutinib Tablet Compared to Capsules in Healthy Adult Participants Zanubrutinib - Healthy Volunteers | Phase 1 | Completed | BeiGene | 58 | 2023-03-07 | 2024-10-26 |
| Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors IMX-110 combined with Tislelizumab - Advanced Solid Tumor | Phase 1 / Phase 2 | Unknown | Immix Biopharma, Inc. | 60 | 2023-02-03 | 2023-08-08 |
| A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer Alcestobart, Tislelizumab, Bevacizumab or Bevacizumab biosimilar - Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | Phase 1 / Phase 2 | Active not recruiting | BeiGene | 113 | 2023-01-29 | 2026-07-23 |
Showing 20 of 74. Sign in to see all of them.
Stomach Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Lymphoma, Large B-Cell, Diffuse (4) · Neoplasm Metastasis (4) · Triple Negative Breast Neoplasms (4) · Breast Neoplasms (3) · Carcinoma, Hepatocellular (3) · Colorectal Neoplasms (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma (3) · Lymphoma, B-Cell, Marginal Zone (3) · Lymphoma, Mantle-Cell (3) · Neoplasms (3) · Small Cell Lung Carcinoma (3) · Endometrial Neoplasms (2)
tislelizumab (29) · zanubrutinib (19) · pamiparib (6) · Carboplatin (4) · Itraconazole (4) · BGB-283 (3) · Capecitabine (3) · Docetaxel (3) · Oxaliplatin (3) · Paclitaxel (3) · Pemetrexed (3) · sitravatinib (3) · 130-nm albumin-bound paclitaxel (2) · Cisplatin (2) · Drug Therapy (2)
United States (38) · China (32) · Australia (31) · South Korea (12) · New Zealand (11) · Spain (6) · Taiwan (5) · United Kingdom (5) · France (4) · Italy (4) · Germany (3) · Moldova (3) · Georgia (2) · Japan (2) · Poland (2)
William Novotny, MD (4) · William Novotony, MD (2) · Baohui Han, MD, PhD (1) · David Schiff, MD (1) · Florian Lordick, Prof. Dr. (1) · Jayesh Desai, MD (1) · Juan P Alderuccio, MD (1) · Lei Zhao (1) · Lu Zhang, M.D. (1) · Michael Millward, MD (1) · Ranjit Bindra, MD (1) · Salah Eddin Al-Batran, Prof. Dr. (1)
PMID 32182156, PMID 35900694, PMID 36879284, PMID 38502198, PMID 38775302, PMID 29439186, PMID 31378459, PMID 32031037, PMID 32144955, PMID 32540858, PMID 33022066, PMID 33128299, PMID 33772633, PMID 33876576, PMID 34152395, PMID 34473343, PMID 34795408, PMID 35383885, PMID 35390135, PMID 36480811, PMID 36797356, PMID 37145975, PMID 37474720, PMID 37857528, PMID 38197138, PMID 38970256, PMID 39563886, PMID 41202501, PMID 41324998, PMID 41824782, PMID 42337921, PMID 42667590
2023 (3), 2017 (2), 2018 (2), 2016 (1), 2019 (1), UM1CA137443 (1)